<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03534726</url>
  </required_header>
  <id_info>
    <org_study_id>827516</org_study_id>
    <nct_id>NCT03534726</nct_id>
  </id_info>
  <brief_title>Edema and Fibrosis CMR Imaging in Cardiomyopathy</brief_title>
  <official_title>Edema and Fibrosis Cardiac Magnetic Resonance Imaging in Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      7 Tesla MRI is a new magnetic field strength that has become available at Penn for&#xD;
      cardiovascular MRI. This new scanner has potential to improve assessment of cardiovascular&#xD;
      disease due to its increased signal-to-noise ratio, higher spatial resolution, and response&#xD;
      to magnetic properties of tissue at high field. The purpose of this study is to assess the&#xD;
      feasibility of 7 T CMR. Secondly, we wish to investigate its use, to improve clinical and&#xD;
      research MRI. Altogether, 7 T may permit better clinical diagnosis of cardiomyopathy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>ejection fraction</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Cardiomyopathies</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>Patients with cardiomyopathy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal subjects</arm_group_label>
    <description>No prior history of heart disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>7 T CMR</intervention_name>
    <description>7 tesla MRI device</description>
    <arm_group_label>Normal subjects</arm_group_label>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The eligible population are cardiomyopathy patients and normal volunteers.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects between the ages of 20-70 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Advanced renal disease (estimated GFR rate &lt; 30 mL/min) or hypersensitivity to&#xD;
             gadolinium contrast agent.&#xD;
&#xD;
          -  Presence of cardiac pacemaker or implanted cardioverter defibrillator&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
&#xD;
          -  Other contraindications to MRI (such as claustrophobia)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter R Witschey, Ph.D.</last_name>
      <phone>215-662-2310</phone>
      <email>witschey@pennmedicine.upenn.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 11, 2018</study_first_submitted>
  <study_first_submitted_qc>May 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2018</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

